In 2012, Berry founded Seres Therapeutics, which pioneered microbiome therapeutics. The foundational insight behind the company was the unique recognition at the time that the microbiome is an organ, and needs to be treated as such when developing drugs to positively transform the lives of patients. The company raised over $130M as a private company, including a $65M investment from Nestle Health Sciences. Seres publicly listed on the Nasdaq under the symbol MCRB in June 2015, raising $134M. The company's stock had the second best first day performance of any stock after its IPO since 2000, reaching a valuation of $2B. Seres signed a partnership valued at $2B with Nestle Health Sciences in early 2016.
Seres lead, SER-109 was advanced into the clinic for recurrent C. difficile where it clinically cured 29 out of 30 patients in its first clinical trial. The FDA has granted SER-109 Orphan Drug, as well as Breakthrough Therapy, designations. Most recently, SER-109 had a positive topline readout for its Phase 3 trial in treatment recurrent C. difficile infection.
The company is also developing therapeutics for ulcerative colitis, metabolic diseases, and other infectious disease. A Phase 1b clinical trial was launched testing SER-287 in ulcerative colitis in 2015 which showed positive objective responses in its topline readout.
In 2014, Berry founded Indigo to create seed treatments that optimize the health of a plant to increase yield. Indigo uses natural microbiology and technology to improve sustainability, with products currently used for five major row crops. The company raised over $200M in 2017 with a valuation of over $1.4B, having raised one of Boston's biggest financing rounds in 2017 and making it a unicorn, after having raised the largest private agtech financing round in history in 2016 at 100M. The company was named #1 on the CNBC 2019 Disruptor 50 List and #3 on the 2020 List. The company has raised over $850M since inception with a valuation of $3.5B.
In 2009, Berry founded Axcella Health, which is pioneering defined a new approach to treating complex diseases and supporting health using Endogenous Metabolic Modulators as a new therapeutic product class. The company's unique platform has allowed it to rapidly generate multiple clinical candidates across liver diseases, neurological conditions, muscle diseases, and beyond, with multiple products in clinical trials. The company was named by Forbes as the hottest healthcare startup in 2015. Axcella announced positive data in hepatic encephalopathy in August on 2020, and in NASH in September 2020.
Berry launched KSQ Therapeutics in 2015 along with academic founders David M. Sabatini, Jonathan Weissman, and Bill Hahn. The company has raised over $150M in financing, and is pioneering CRISPRomics as a unique tool to define the precise function that each human gene plays across a multitude of diseases. KSQ's approach has allowed it to advance a pipeline of cancer and immune disease drug programs against novel therapeutic nodes to pioneer a new set of disease-tailored medicines.
In 2014, Berry founded Evelo Biosciences, to pioneer monoclonal microbial--single bacteria that can drive the immune system specifically, reproducible, in a dose-dependent manner. Monoclonal microbials leverage the privileged interface between bacteria and the immune system in order to achieve unprecedented immune control. The company is developing therapeutics to treat cancer as well as autoimmune and inflammatory diseases. Evelo's pipleline include multiple therapeutic candidates including a treatment for COVID-19, triple negative breast cancer, and Psoriasis.
In 2007, Berry founded Joule Unlimited, which is developing Solar Fuels—drop-in fuels produced directly from the sun. Joule pioneered solar fuels through a new technology that converts sunlight, carbon dioxide, and salt water into drop-in fuels for prices as low as $20. In March 2010 and again in March 2011, Joule was named by Technology Review as one of the 50 Most Innovative Companies. Joule was named as one of the 10 most important emerging technologies in 2011. Joule's unique and innovative approach to fuels led to its being named a Technology Pioneer by the World Economic Forum in 2012 and to its receiving the Silver Medal in the 2011 Wall Street Journal Technology Innovation Awards. Berry has been recognized multiple times as one of the top people in bioenergy by Biofuels Digest.
In 2005, Berry founded LS9, with Chris Somerville, Jay Keasling, and George M. Church, which uses synthetic biology to engineer microorganisms to covert sustainable, plant-based materials into low-carbon fuels and chemicals. LS9 has successfully built on technologies he invented with other co-founders to produce a scalable platform for renewable fuels and chemicals. This technology was successfully scaled to a fully operational 135,000L facility in Okeechobee, Florida. The impact and importance of LS9's technology led to its being named a Technology Pioneer by the World Economic Forum in 2008 and its being awarded the Presidential Green Chemistry Challenge Award in 2010, the U.S. Environmental Protection Agency’s highest environmental honor. LS9 was acquired by Renewable Energy Group in 2014.
Berry was born in 1978. He graduated Hackley School in Tarrytown, NY in 1996. Berry graduated with a S.B. Phi Beta Kappa and Sigma Xi from the Massachusetts Institute of Technology in 2000. He earned his M.D. from Harvard Medical School and his PhD from the Massachusetts Institute of Technology with Robert Langer and Ram Sasisekharan, completing his dual degree through the Harvard-MIT Program of Health Sciences and technology in just over 5 years as one of the fastest combined degrees in the history of the program. Berry was recognized in 2005 with the Lemelson-MIT Student Prize for invention and innovation. He also started multiple companies during his graduate education.
Berry has been an author of 1